GEN Exclusives

More »

GEN News Highlights

More »
Jul 19, 2007

Codexis Takes Over BioCatalytics

  • Codexis has acquired BioCatalytics, a private company that produces custom and off-the-shelf enzymes. Biocatalysis is a clean technology that uses specialized enzymes to accelerate and improve the economics and environmental impact of chemical reactions. "This acquisition creates a market leader in biocatalysis, bringing the power of clean biobased manufacturing technology to customers seeking alternatives to undesirable or unsustainable chemical processes," says Alan Shaw, Ph.D., president and CEO.

    "BioCatalytics, one of the most respected companies in this growing industry sector, offers a broad catalog of enzyme catalysts and technology services long used by the life science industry in chemical synthesis. Our expanded company will provide a broad product and service platform to serve the pharmaceutical industry worldwide and will also offer exciting new enzyme technologies to our bioindustrial partners."

    Codexis reports that the U.S. enzyme market is expected to increase from $1.6 billion in 2005 to $2.2 billion by 2010, according to industry estimates.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »